OBJECTIVE: Plasma cytokine concentrations from patients with head and neck squamous cell carcinoma (HNSCC) were measured to determine whether the potential modulation of host Th1 vs Th2 immune responses are associated with advanced clinical disease. STUDY DESIGN AND SETTING: The concentrations of IL-4, IL-6, IL-10, and IL-12 were measured in the plasma of 58 patients with histologically proven HNSCC. These data were examined with respect to the histologic size (T-stage) of the primary tumor, and presence of nodal metastasis. RESULTS: The concentrations of IL-12 were greater from patients without nodal metastasis, and with T(1)/T(2)-stage tumors. IL-10 levels were greater from patients with nodal metastasis, and with T(3)/T(4)-stage tumors. The concentrations of IL-6 were greater from patients with T(3)/T(4)-stage tumors. CONCLUSIONS: Using parameters of primary tumor size and presence of nodal metastasis, patients with advanced HNSCC have significantly less plasma IL-12 levels, and greater plasma IL-10 and IL-6 levels. SIGNIFICANCE: Patients with advanced HNSCC have a potentially diminished Th1 immune response, and a stronger potential Th2 immune response when compared to that of patients with less advanced disease. EBM RATING: D-5.
OBJECTIVE: Plasma cytokine concentrations from patients with head and neck squamous cell carcinoma (HNSCC) were measured to determine whether the potential modulation of host Th1 vs Th2 immune responses are associated with advanced clinical disease. STUDY DESIGN AND SETTING: The concentrations of IL-4, IL-6, IL-10, and IL-12 were measured in the plasma of 58 patients with histologically proven HNSCC. These data were examined with respect to the histologic size (T-stage) of the primary tumor, and presence of nodal metastasis. RESULTS: The concentrations of IL-12 were greater from patients without nodal metastasis, and with T(1)/T(2)-stage tumors. IL-10 levels were greater from patients with nodal metastasis, and with T(3)/T(4)-stage tumors. The concentrations of IL-6 were greater from patients with T(3)/T(4)-stage tumors. CONCLUSIONS: Using parameters of primary tumor size and presence of nodal metastasis, patients with advanced HNSCC have significantly less plasma IL-12 levels, and greater plasma IL-10 and IL-6 levels. SIGNIFICANCE: Patients with advanced HNSCC have a potentially diminished Th1 immune response, and a stronger potential Th2 immune response when compared to that of patients with less advanced disease. EBM RATING: D-5.
Authors: Sarah M Russell; Melissa G Lechner; Lucy Gong; Carolina Megiel; Daniel J Liebertz; Rizwan Masood; Adrian J Correa; Jing Han; Raj K Puri; Uttam K Sinha; Alan L Epstein Journal: Oral Oncol Date: 2011-06-29 Impact factor: 5.337
Authors: David D Walker; Travis D Reeves; Anna-Maria de Costa; Corinne Schuyler; M Rita I Young Journal: Cytokine Date: 2012-03-24 Impact factor: 3.861
Authors: A J Montero; C M Diaz-Montero; R E Millikan; J Liu; K-A Do; S Hodges; E Jonasch; B W McIntyre; P Hwu; N Tannir Journal: Ann Oncol Date: 2009-06-18 Impact factor: 32.976
Authors: Ramez Philips; Chihun Han; Brian Swendseid; Joseph Curry; Athanassios Argiris; Adam Luginbuhl; Jennifer Johnson Journal: Front Oncol Date: 2021-07-01 Impact factor: 6.244